BDK Advokati/Attorneys at Law advised Mylan

BDK advised Mylan in relation to the acquisition of Abbott’s established products business (EPD Business) in Bosnia and Herzegovina, as part of a USD 5.3 billion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. BDK team was led by Partners Vladimir Dašić and Mirjana Mladenović on the corporate law and transactional side […]

Blog 1

Serbian Commission accepts legally binding commitments offered by Telekom Srbija

In a previous post, we wrote about the market test carried out by the Serbian Commission for Protection of Competition in relation to the commitments proposal by Telekom Srbije made in a probe involving the allegations of abuse of dominance. On 14 November, the Commission adopted all of the commitments proposed by Telekom. Relying on the decisions […]

Blog 1

Protection of confidential data by the Montenegrin Agency for Protection of Competition

The Montenegrin Agency for Protection of Competition on 30 September 2014 published the Notice on Protection of Confidential Business Information in Proceedings before the Agency. The Notice sets out the types of information which can be deemed confidential and the procedure for granting the status of confidentiality. Who can request confidentiality? In the proceedings before the Agency, […]

BDK launches Life Sciences & Healthcare practice

BDK’s newly formed Life Sciences and Healthcare practice group synergizes our firm’s existing capacity in regulatory work, corporate, finance, competition, data protection, IP, product liability and litigation, upgrading it with a special industry focus. The move to create a dedicated life sciences and healthcare group builds on the firm’s existing credentials with multinational pharmaceutical companies, […]